Deruxtecan(CAS: 1599440-13-7)

Deruxtecan is a novel antibody-drug conjugate (ADC) used in cancer therapy. It consists of an anti-nectin-4 antibody linked to a potent topoisomerase I inhibitor. Deruxtecan has a molecular weight of approximately 12,000 Da and is designed for targeted delivery of chemotherapy to nectin-4-expressing tumors.

Deruxtecan is primarily used as a treatment for patients with advanced or metastatic solid tumors, particularly those expressing the nectin-4 antigen. It is approved for use in certain types of breast cancer, lung cancer, and other cancers. Deruxtecan is administered intravenously and acts by selectively delivering cytotoxic payload to cancer cells expressing nectin-4.

Deruxtecan is generally considered safe when used under medical supervision. However, it can cause side effects such as nausea, fatigue, and diarrhea. Patients should be monitored closely, and appropriate precautions should be taken to manage potential adverse reactions. Always consult with a healthcare professional regarding the safety of Deruxtecan.

Deruxtecan should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. It must be kept in its original container to maintain its stability. Avoid freezing and ensure that the product is not exposed to excessive heat or humidity. Store it out of reach of children and in a secure location to prevent accidental exposure or misuse.